What is HC Wainwright’s Estimate for VKTX Q2 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at HC Wainwright cut their Q2 2025 EPS estimates for Viking Therapeutics in a research note issued to investors on Thursday, April 24th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn ($0.42) per share for the quarter, down from their previous forecast of ($0.35). HC Wainwright has a “Buy” rating and a $102.00 price target on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($1.76) EPS.

A number of other equities research analysts also recently weighed in on the company. Cantor Fitzgerald started coverage on Viking Therapeutics in a report on Monday. They issued an “overweight” rating and a $104.00 price target for the company. Truist Financial reissued a “buy” rating and set a $75.00 target price (down from $95.00) on shares of Viking Therapeutics in a report on Monday. Citigroup started coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They issued a “neutral” rating and a $38.00 price target for the company. Maxim Group dropped their price objective on shares of Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, The Goldman Sachs Group started coverage on shares of Viking Therapeutics in a report on Tuesday, April 8th. They issued a “neutral” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $87.15.

Viking Therapeutics Stock Up 7.7 %

Shares of Viking Therapeutics stock opened at $27.94 on Monday. The business has a 50-day moving average price of $26.27 and a 200 day moving average price of $39.98. Viking Therapeutics has a fifty-two week low of $18.92 and a fifty-two week high of $81.86. The firm has a market cap of $3.14 billion, a P/E ratio of -27.94 and a beta of 0.84.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). During the same quarter last year, the business posted ($0.26) EPS. The business’s revenue for the quarter was up .0% on a year-over-year basis.

Institutional Trading of Viking Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. increased its stake in shares of Viking Therapeutics by 75.9% during the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 309 shares during the period. YANKCOM Partnership bought a new position in Viking Therapeutics during the 4th quarter valued at $33,000. FIL Ltd increased its position in shares of Viking Therapeutics by 116.8% during the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 648 shares during the period. CIBC Private Wealth Group LLC increased its position in shares of Viking Therapeutics by 170.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 851 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of Viking Therapeutics by 64.8% in the 1st quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company’s stock worth $33,000 after buying an additional 536 shares in the last quarter. 76.03% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Sarah Kathryn Rouan bought 1,240 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The stock was purchased at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the transaction, the director now directly owns 1,240 shares of the company’s stock, valued at approximately $29,946. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.